Continued approval for this indication is contingent upon verification and description of clinical benefit in a confirmatory trial.

Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic ...

After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in ...

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

Continued approval of zongertinib may be contingent upon verification of clinical benefit in a confirmatory trial.

A Right To Information (RTI) response from Mumbai’s three biggest civic-run hospitals shows that only 0.3% of respiratory ...

Beginning treatment for your lung cancer often brings questions surrounding what side effects will be experienced, according ...

The impact that Bernie Williams’ father had on him was immeasurable. Without the sage advice and caring personality of ...

Detailed price information for Gossamer Bio Inc (GOSS-Q) from The Globe and Mail including charting and trades.

Approval followed priority review and was based on response rates and duration of response demonstrated in the phase 1b Beamion LUNG-1 trial.

The FDA approved Hernexeos for adults with unresectable or metastatic non-squamous non-small cell lung cancer.

The U.S. Food and Drug Administration said on Friday it has approved Boehringer Ingelheim's drug for patients with a type of ...